Irish pharmaceuticals group Uniphar has announced a deal to buy US-based Diligent Health Solutions for up to $27m.

DHS is a US-based healthcare communications company and provides enhanced contact centre services as it focuses on the delivery of medical information to patients and healthcare practitioners. 

Uniphar said the deal is "highly complementary" to its footprint and present capabilities.

It will enhance the company's target of building connectivity between its clients and key healthcare stakeholders, Uniphar added. 

DHS's workforce of over 80 staff include a combination of healthcare practitioners and subject matter experts. Its workforce will continue to operate from its two locations in the US - Philadelphia and Virgina. 

Uniphar said the total potential cost of the acquisition is $27m, with $10m paid upfront with the deferred element linked to EBITDA performance over the next four years. 

Ger Rabbette, CEO of Uniphar, said today's deal for Diligent Health Solutions, with its combination of highly trained people and enhanced contact centre technologies, will further extend Uniphar's relationships with its US client base.

"Our organisation is excited about the role telehealth will play in adding value to our global expanded access offering and creates positive revenue synergy opportunities across both of our Commercial and Clinical and Product Access divisions," Ger Rabbette said.